by ANDREW ALEXIS, MD, MPH; JERRY TAN, MD; MARCO ROCHA, MD, PhD; DELPHINE KEROB, MD; ANN’LAURE DEMESSANT, PharmD; FATIMATA LY MD; YAN WU, MD, PhD; MUKTA SACHDEV, MD; and ICHIRO KUROKAWA, MD, PhD

Dr. Alexis is with the Department of Dermatology, Weill Cornell Medicine, New York, New York. Dr. Tan is with Western University, Windsor in Ontario, Canada. Dr. Rocha is with the Department

of Dermatology, Federal University of São Paulo in São Paulo, Brazil. Drs. Kerob and Demessant are with La Roche-Posay Laboratoire Dermatological Beauty in Paris, France. Dr. Ly is with the

Dermatology Department at the University Cheikh Anta Diop of Dakar in Dakar, Senegal, West Africa. Dr. Wu is with the Department of Dermatology, Peking University First Hospital in Beijing, China. Dr. Sachdev is with the Department of Dermatology, Manipal Hospital in Bangalore, India. Dr. Kurokawa is with the Department of Dermatology at the Meiwa Hospital in Hyogo, Japan.

J Clin Aesthet Dermatol. 2024;17(9):16–22.

Acne is a common skin disease associated with a range of sequelae. These include scarring and dyspigmentation, emotional and psychosocial disturbances, and occupational problems, in part because acne often manifests on the face, in addition to other body areas, and is highly visible. Worldwide, the prevalence of acne is estimated at 9.4 percent; it is most common in adolescents but also affects a relatively high proportion of adults. Early studies of acne epidemiology were conducted primarily in the United States and the United Kingdom. In more recent decades, data have been increasing for other areas of the world. There has also been more attention devoted to how acne may present and be managed in individuals with skin of color (i.e., the broad and diverse range of populations that self-identify as belonging to a non-White racial/ethnic group and share characteristics such as higher skin phototypes and propensity toward hyperpigmentation). This review seeks to highlight aspects of acne that may be unique to skin of color.

KEYWORDS: Acne vulgaris, skin of color, ethnicity, race

FUNDING: Funding for this study was provided by La Roche-Posay.

DISCLOSURES: Dr Alexis has served as a consultant and/or advisory board member for Leo, Novartis, Galderma Laboratories LP, Sano Regeneron, Dermavant, Unilever, Beiersdorf, Valeant, L’Oreal, Bristol Meyers Squibb, Scientis, Bausch Health, UCB, Arcutis, Janssen, Allergan, Almirall, AbbVie, and Sol-Gel. Dr Tan has received grants, honoraria, or served as a consultant for Bausch, Boots Walgreens, Cipher, Cutera, Galderma, La Roche Posay, Novartis, Pierre Fabre, and P zer. Dr Rocha has served as an advisor and/or received honoraria from Galderma, Pierre-Fabre, Eucerin, La Roche Posay, and Leo Pharma. Dr Kerob and Dr Demessant are employees of L’Oreal. Dr Ly has served as consultant and received honoraria from La Roche Posay. Pr Wu and Dr Sachdev have served consultants for L’Oreal. Dr. Kurokawa has received research grants from Aisin Corporation and served as a consultant for L’Oreal.

CORRESPONDENCE: Delphine Kerob, MD; Email: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。